The presentation videos and slides for speakers’ lectures will be made available provided that the speakers have granted us permission to do so.
COVID-19 Clinical Forum 2024
Related Enduring Materials
Enduring Materials
Tuesday, 17 September -
Kathryn Stephenson, MD, MPH
Updated Recommendations for the SARS-CoV-2 Vaccination
Harvard Medical School / Ragon Institute / Beth Israel Deaconess Medical Center, United States
Nirmatrelvir/Ritonavir for the Treatment of Long COVID: Findings from the STOP-PASC Clinical Trial
Update on COVID-19 Therapeutics
Overview
Thank you
We are pleased to reflect on the highly successful webinar for the COVID-19 Clinical Forum 2024.
The Program Chair and organizers would like to thank the speakers, chairs, and all participants for their contribution to this meeting!
Special thanks to the webinar support: MSD. Without their contribution, this webinar would not have been made possible.
About this Program
The COVID-19 Clinical Forum 2024 was a series of 2 online interactive meetings (90 minutes each) that provided continuing education to a wide range of healthcare professionals, including infectious disease doctors, pulmonologists, and virologists.
The program encompassed a broad range of topics, from COVID-19 epidemiology, treatments, post-COVID conditions & clinical manifestations, clinical management, pathophysiology, prevention, and vaccines, to diagnostics and public health strategies.
This program is continuously updated as new information emerges and provides the latest COVID-19 data from renowned experts to clinicians worldwide. The program was designed to provide state-of-the-art, concise, and comprehensive lectures, and to facilitate participation from healthcare professionals from around the world.
Program Directors
General Information
Topics of Interest
The program has encompassed a wide range of topics, from vaccine research, immune response, SARS CoV-2 infection, diagnostics, and the use of artificial intelligence to contain the spread of the virus, to clinically orientated lectures on emerging treatment options and novel insights into disease pathophysiology.
The series has included continuous updates on COVID-19 infection control, epidemiology, prevention, diagnosis, pathogenesis, pathophysiology, clinical manifestations and management, emerging variants, therapeutic options, vaccine development and Implementation, public health measures, and treatments.
The series has included continuous updates on COVID-19 infection control, epidemiology, prevention, diagnosis, pathogenesis, pathophysiology, clinical manifestations and management, emerging variants, therapeutic options, vaccine development and Implementation, public health measures, and treatments.
Who Should Attend?
-Healthcare providers;
-Infectious disease clinicians;
-Clinical virologists;
-Primary care physicians;
-Intensivists;
-Researchers;
-Nurses;
-Pharmacists;
-Others interested in staying informed on new insights and developments.
-Infectious disease clinicians;
-Clinical virologists;
-Primary care physicians;
-Intensivists;
-Researchers;
-Nurses;
-Pharmacists;
-Others interested in staying informed on new insights and developments.
Learning Objectives
After participating in this activity, participants will be able to:
- Describe therapeutic options for the treatment of COVID-19
- Interpret clinical data on the use of Nirmatrelvir/Ritonavir for the treatment of long COVID
- Understand the impact of SARS-CoV-2 infection during pregnancy on mother and child health
- Describe therapeutic options for the treatment of COVID-19
- Interpret clinical data on the use of Nirmatrelvir/Ritonavir for the treatment of long COVID
- Understand the impact of SARS-CoV-2 infection during pregnancy on mother and child health
Practical Information
Schedule
-Tuesday, 19 March 2024 at 20:00 CET / 14:00 EST
-Tuesday, 17 September 2024 at 20:00 CEST / 14:00 EDT
-Tuesday, 17 September 2024 at 20:00 CEST / 14:00 EDT
Certificate of Attendance
A digital certificate of attendance will be sent to participants that have successfully completed the program and post-meeting survey.
Language
The official language of the webinar is English. Translation will not be provided.
Liability & Insurance
By registering for the webinar, participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Previous Edition
The presentation videos and slides for speakers’ lectures are made available, provided that they have granted us permission to do so.
Tuesday, 19 March -
Priscilla Hsue, MD
Update on COVID-19 Therapeutics
Nirmatrelvir/Ritonavir and Long Covid: Where are we Now?
University of California, San Francisco; Zuckerberg San Francisco General Hospital, United States
COVID-19 in the Pregnancy and Postpartum Period
Support
The COVID-19 Clinical Forum 2024 was supported by a grant from MSD. MSD has had no input into the selection of speakers or the content of the materials and presentations.
Endorsers
The COVID-19 Clinical Forum 2024 webinar series was endorsed by the following organizations:
Accreditation
EACCME® Accreditation
The COVID-19 Clinical Forum 2024, Virtual, Netherlands 17/09/2024 - 17/09/2024, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1.5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
CME Accreditation
An application for CME accreditation will be submitted to the European Accreditation Council for Continuing Medical Education (EACCME) for each edition.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Please note that CME accreditation is only provided for delegates that attend the event livestream and submit the post-meeting survey.
How can I receive a CME-accredited Certificate of Attendance?
In order to be eligible to receive a CME-accredited Certificate of Attendance, you must have followed the full program and complete the post-evaluation survey. Please check your junk/spam inbox if you cannot find the email containing your link to the survey. If you followed the program and did not receive an email with a link to the survey, please email us at Karen.Lam@amededu.com.
The post-evaluation survey will be online for 1 week after the livestream. Please complete the survey within this time in order to receive your CME-accredited Certificate of Attendance. Once the survey is closed, it cannot be reopened.
Previous Editions
Language
Related Programs
